Mark Cziraky, PharmD, CLS: The Future of Biosimilars

Mark Cziraky, PharmD, CLS, describes what he sees as the future of the biosimilars space.
July 26, 2018


What do you see as the future for the biosimilar space?

Well, I think a big part of it is we’re hopeful that these therapies become a big opportunity to reduce costs in the healthcare system while getting the intended benefits of these therapies. 

You look at the generic marketplace and biopharmaceuticals in general, and while it’s taken some time, there are significant cost savings to be appreciated from using generic therapies. So, if you apply that to the biosimilar marketplace, and hopefully we’ll see again significant cost-reductions in the acquisition costs in the use of these therapies, and we’ll see benefits in that area too.


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.